Global Swab and Viral Transport Medium Market Growing Rapidly Due to Rising Demand from COVID-19 Pandemic
|
By LabMedica International staff writers Posted on 14 Sep 2020 |

Illustration
The global swab and viral transport medium market (VTM) was valued at USD 0.9 billion in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030 to reach USD 2.2 billion by 2030, driven by increased demand during the COVID-19 (coronavirus) pandemic.
Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture. Rapid antigen testing and molecular assay experiments have fueled the demand for swab and VTM during the ongoing coronavirus crisis. Long-term freezers and direct fluorescent antibody (DVA) applications are creating incremental opportunities for companies in the swab and VTM market.
These are the findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
VTM enables safe transfer of viruses, chlamydia, and mycoplasma for research, including conventional cell culture methods, diagnostic tests, and molecular biology techniques. Swabs collected and transported dry or in saline are compared to commercially available swab/medium combinations for PCR detection of influenza, enterovirus, herpes simplex virus, and adenovirus. In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The transport medium segment is anticipated to expand at a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Based on application, the viral infection diagnosis segment held a significant share of the global swab and VTM market in 2019.
Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM in the region. Rise in awareness about the benefits of prevention of diseases and increase in healthcare expenditure augment the swab and VTM market in North America. Asia Pacific held the second-largest share of the global swab and VTM market in 2019. The growth of the swab and VTM market in the region can be attributed to rise in prevalence of infectious diseases. The market in Asia Pacific is likely to grow at a rapid pace during the forecast period. The development of vaccines and other pharma products to cope with diseases and rise in awareness leading to routine check-up and diagnosis are the major factors anticipated to fuel the growth of the swab and VTM market in the region.
Companies in the swab and VTM market are innovating in kits containing vials, double-ended flocked swabs, antibiotics, and other items that inhibit bacterial or fungal contamination. They are focusing on improved formulation of Hanks solution to contain the reproduction of bacterial and fungal flora. Innovative VTM products are bolstering market growth. Manufacturers in the swab and VTM market are innovating in products that facilitate rapid antigen testing, viral culture, and molecular-based assay. They are adopting the vertically integrated approach to manufacture swab and VTM in order to gain complete control over the entire process.
3 dimensional (3D) printers are being used to produce cost-efficient nasopharyngeal swabs. Companies in the swab and VTM market are using fused deposition modelling (FDM) printers to manufacture nasopharyngeal swab in a cost-efficient manner. Manufacturers are using FDA-approved biocompatible materials in swab such as polylactic acid (PLA) plastic filament. They are making use of renewable resources such as sugarcane and tapioca roots to produce 3D printed swab. On the other hand, companies are using flocking methods to electrostatically deposit small fibers of synthetic materials onto an adhesive-coated surface to produce nasopharyngeal swabs. In order to eliminate the need for adhesives, manufacturers are using mini blunt-ended hooks to secure polyester threads of nasopharyngeal swabs.
Related Links:
Transparency Market Research
Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture. Rapid antigen testing and molecular assay experiments have fueled the demand for swab and VTM during the ongoing coronavirus crisis. Long-term freezers and direct fluorescent antibody (DVA) applications are creating incremental opportunities for companies in the swab and VTM market.
These are the findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
VTM enables safe transfer of viruses, chlamydia, and mycoplasma for research, including conventional cell culture methods, diagnostic tests, and molecular biology techniques. Swabs collected and transported dry or in saline are compared to commercially available swab/medium combinations for PCR detection of influenza, enterovirus, herpes simplex virus, and adenovirus. In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The transport medium segment is anticipated to expand at a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Based on application, the viral infection diagnosis segment held a significant share of the global swab and VTM market in 2019.
Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM in the region. Rise in awareness about the benefits of prevention of diseases and increase in healthcare expenditure augment the swab and VTM market in North America. Asia Pacific held the second-largest share of the global swab and VTM market in 2019. The growth of the swab and VTM market in the region can be attributed to rise in prevalence of infectious diseases. The market in Asia Pacific is likely to grow at a rapid pace during the forecast period. The development of vaccines and other pharma products to cope with diseases and rise in awareness leading to routine check-up and diagnosis are the major factors anticipated to fuel the growth of the swab and VTM market in the region.
Companies in the swab and VTM market are innovating in kits containing vials, double-ended flocked swabs, antibiotics, and other items that inhibit bacterial or fungal contamination. They are focusing on improved formulation of Hanks solution to contain the reproduction of bacterial and fungal flora. Innovative VTM products are bolstering market growth. Manufacturers in the swab and VTM market are innovating in products that facilitate rapid antigen testing, viral culture, and molecular-based assay. They are adopting the vertically integrated approach to manufacture swab and VTM in order to gain complete control over the entire process.
3 dimensional (3D) printers are being used to produce cost-efficient nasopharyngeal swabs. Companies in the swab and VTM market are using fused deposition modelling (FDM) printers to manufacture nasopharyngeal swab in a cost-efficient manner. Manufacturers are using FDA-approved biocompatible materials in swab such as polylactic acid (PLA) plastic filament. They are making use of renewable resources such as sugarcane and tapioca roots to produce 3D printed swab. On the other hand, companies are using flocking methods to electrostatically deposit small fibers of synthetic materials onto an adhesive-coated surface to produce nasopharyngeal swabs. In order to eliminate the need for adhesives, manufacturers are using mini blunt-ended hooks to secure polyester threads of nasopharyngeal swabs.
Related Links:
Transparency Market Research
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








